Pancreatic cancer is the fourth leading cause of death from cancer, and while family physicians in Canada only see 1 case a year, the number of cases is expected to increase as the population ages. A review in CMAJ (Canadian Medical Association Journal) provides an evidence-based overview of diagnosis and treatment of the disease for general physicians.
The main risk factor for pancreatic cancer is smoking, although about 20% of patients have a family history of the disease. Symptoms usually manifest 10 years after the start of the disease, which means screening has theoretical benefits although there are no evidence-based standardized screening protocols. For people with hereditary pancreatic cancer, screening on a limited investigational protocol begins 10 years before the youngest relative was diagnosed or at age 40, whichever comes first. Diagnostic tests include abdominal ultrasounds and CT scans, the latter being used to diagnose the stage of cancer and the location of the position of the tumour in relation to vessels and other organs.
Surgery can be successful for cancers that have not spread beyond the pancreas, with a 5-year survival of 15%, but higher in some cases (25%). Adjuvant chemotherapy, especially with gemcitabine, which has lower toxicity than some treatments, is recommended for all patients. The benefits of radiation therapy are uncertain according to the evidence.
“Accelerated progress in understanding pancreatic cancer relies on robust partnerships between clinicians and basic scientists, such as the current global effort to develop more integrated translational pancreatic cancer programs. Next-generation sequencing has revolutionized the field of pancreatic cancer genetics,” the authors write.
The sequencing of genomes of 750 pancreatic specimens will help in understanding the disease and ultimately lead to “personalized” treatment.
Canadian Medical Association Journal